A conventional biopsy is a process feared by patients affected by malignant tumors. The very thought of the procedure, which slices through a tumor is very disturbing, while the surgery, which gets malignancy ascertained is also very painful, while the actual treatment is the real difficult part. Researches have been trying to perfect “Liquid Biopsy”, which much more less invasive and harmful to the body.
The use of blood for diagnosis of many conditions has been the first choice of doctors. With this liquid biopsy, the inconvenient procedure for this diagnosis is a thing of the past. This blood test, which is similar to others, looks in the blood stream to find traces of DNA that is contaminated with malignant cells. The entire procedure would be seen as very good news for the patients, as the diagnosis is as easy to obtain as for any other blood test.
This innovation also plays a much larger role in the actual treatment, as opposed to biopsies. Over the length of treatment, the Liquid Biopsy can be carried out at very specific intervals to research the effectiveness of the treatment. Most malignant cells tend to be resistant when the treatment is given. The actual efficacy of the treating process can be monitored constantly as observed by Dr. Jose Baselga, physician in chief & CMO at Memorial Sloan Kettering Cancer Center .
Baselga is extremely happy with this innovation and believes that could forever change the course of investigation and treatment of Cancer.
The medical community is requesting additional proof on the actual efficiency of the method. Until now, research have been conducted only on some types of cancer, and the scale of this studies was quite small. Reports have announced that these results are promising, but larger-scale studies could reveal how much efficient this method is.
The Lancet Oncology offered details of a study carried out by the National Cancer Institute. The study was centered around 126 patients that suffer from lymphoma. The study was able to determine the accuracy of diagnosis, while also identifying patients whom were not responding efficiently to treatment, after regular monitoring using the liquid test had been done.
Dr. David Hyman, an oncologist at Sloan Kettering said that the procedure is similar to a Bar Code mechanism that could find different forms of malignancy.
Image Source: Global Post